| [1] |
van Hellemond I, Geurts S, Tjan-Heijnen V. Current status of extended adjuvant endocrine therapy in early stage breast cancer[J]. Curr Treat Options Oncol，2018，19(5)：26.
|
| [2] |
Font R, Espinas JA, Barnadas A, et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a populati on-based study in Catalonia, Spain[J]. Breast Cancer Res Treat，2019，175(3)：733-740.
|
| [3] |
Nabieva N, Fehm T, Haberle L, et al. Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: results of the prospective EvAluate-TM study[J]. Eur J Cancer，2018，96：82-90.
|
| [4] |
Tenti S, Correale P, Cheleschi S, et al. Aromatase inhibitors-induced musculoskeletal disorders: current knowledge on clinical and molecular aspects[J]. Int J Mol Sci，2020，21(16)：5625.
|
| [5] |
Mccloskey E. Effects of third-generation aromatase inhibitors on bone[J]. Eur J Cancer，2006，42(8)：1044-1051.
|
| [6] |
Niravath P. Aromatase inhibitor-induced arthralgia: a review[J]. Ann Oncol，2013，24(6)：1443-1449.
|
| [7] |
Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis[J]. Ann Oncol，2011，22(8)：1763-1769.
|
| [8] |
Hershman DL, Loprinzi C, Schneider BP. Symptoms: aromatase inhibitor induced arthralgias[J]. Adv Exp Med Biol，2015，862：89-100.
|
| [9] |
Schaible HG. Spinal mechanisms contributing to joint pain[J]. Novartis Found Symp，2004，260：4-22, 22-27, 100-104, 277-279.
|
| [10] |
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer[J]. J Oncol Pract，2012，8(6)：e149-e157.
|
| [11] |
Islander U, Jochems C, Lagerquist MK, et al. Estrogens in rheumatoid arthritis; the immune system and bone[J]. Mol Cell Endocrinol，2011，335(1)：14-29.
|
| [12] |
Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging[J]. Breast Cancer Res Treat，2007，104(1)：87-91.
|
| [13] |
Bauml J, Chen L, Chen J, et al. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia？[J]. Breast Cancer Res，2015，17：89.
|
| [14] |
Kadakia KC, Snyder CF, Kidwell KM, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer[J]. Oncologist，2016，21(5)：539-546.
|
| [15] |
Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol，2007，25(5)：486-492.
|
| [16] |
Boonstra A, van Zadelhoff J, Timmer-Bonte A, et al. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers[J]. Cancer Nurs，2013，36(1)：52-59.
|
| [17] |
Beckwee D, Leysen L, Meuwis K, et al. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis[J]. Support Care Cancer，2017，25(5)：1673-1686.
|
| [18] |
Servitja S, Martos T, Rodriguez SM, et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance[J]. Ther Adv Med Oncol，2015，7(5)：291-296.
|
| [19] |
Borrie AE, Rose FA, Choi YH, et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients[J]. Breast Cancer Res Treat，2020，183(2)：365-372.
|
| [20] |
Romero S, Su HI, Satagopan J, et al. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors[J]. Breast，2020，49：48-54.
|
| [21] |
Niravath P, Chen B, Chapman JW, et al. Vitamin D levels, vitamin D receptor polymorphisms, and inflammatory cytokines in aromatase inhibitor-induced arthralgias: an analysis of CCTG MA.27[J]. Clin Breast Cancer，2018，18(1)：78-87.
|
| [22] |
Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer[J]. J Clin Oncol，2010，28(23)：3784-3796.
|
| [23] |
Pineda-Moncusí M, Servitja S, Tusquets I, et al. Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study[J]. Breast Cancer Res Treat，2019，177(1)：53-60.
|
| [24] |
Park JY, Lee SK, Bae SY, et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors[J]. J Korean Surg Soc，2013，85(5)：205-211.
|
| [25] |
Chim K, Xie SX, Stricker CT, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survi vors[J]. BMC Cancer，2013，13：401.
|
| [26] |
Bulun SE, Chen D, Moy I, et al. Aromatase, breast cancer and obesity: a complex interaction[J]. Trends Endocrinol Metab，2012，23(2)：83-89.
|
| [27] |
Cooper C, Inskip H, Croft P, et al. Individual risk factors for hip osteoarthritis: obesity, hip injury, and physical activity[J]. Am J Epidemiol，1998，147(6)：516-522.
|
| [28] |
Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis[J]. Lancet Oncol，2008，9(9)：866-872.
|
| [29] |
Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage brea st cancer[J]. J Clin Oncol，2007，25(25)：3877-3883.
|
| [30] |
Egawa C, Hirokaga K, Takao S, et al. Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastr ozole: a prospective multicenter cohort study of patient-reported outcomes[J]. Int J Clin Oncol，2016，21(2)：262-269.
|
| [31] |
Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as a djuvant therapy for operable breast cancer[J]. J Clin Oncol，2006，24(34)：5381-5387.
|
| [32] |
Numazaki R, Miyagi E, Onose R, et al. Historical control study of paclitaxel-carboplatin (TJ) versus conventional platinum-based chemotherapy (CAP) for epithelial ovarian cancer[J]. Int J Clin Oncol，2006，11(3)：221-228.
|
| [33] |
郑帅. 基于COX回归模型的芳香化酶抑制剂相关骨关节痛的影响因素分析[D]. 青岛：青岛大学，2020.
|
| [34] |
Chien HC, Kao Yang YH, Kwoh CK, et al. Aromatase inhibitors and risk of arthritis and carpal tunnel syndrome among taiwanese women with breast cancer: a nationwide claims data analysis[J]. J Clin Med，2020，9(2).
|
| [35] |
Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors[J]. Cancer，2009，115(16)：3631-3639.
|
| [36] |
Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome[J]. Breast，2007，16(3)：223-234.
|
| [37] |
Shi Q, Giordano SH, Lu H, et al. Anastrozole-associated joint pain and other symptoms in patients with breast cancer[J]. J Pain，2013，14(3)：290-296.
|
| [38] |
Nabieva N, Häberle L, Brucker SY, et al. Preexisting musculoskeletal burden and its development under letrozole treatment in early breast canc er patients[J]. Int J Cancer，2019，145(8)：2114-2121.
|
| [39] |
Mao H, Bao T, Shen X, et al. Prevalence and risk factors for fatigue among breast cancer survivors on aromatase inhibitors[J]. Eur J Cancer，2018，101：47-54.
|
| [40] |
钟莹. 补肾强筋胶囊治疗乳腺癌AIMSS的临床研究[D]. 广州：广州中医药大学，2017.
|
| [41] |
Swenson KK, Nissen MJ, Henly SJ, et al. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in wo men with breast cancer receiving aromatase inhibitors[J]. Oncol Nurs Forum，2013，40(6)：549-557.
|
| [42] |
Dottorini L, Catena L, Sarno I, et al. The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor[J]. J Geriatr Oncol，2019，10(2)：356-358.
|
| [43] |
仲姗姗，李蓉，王洁婷，等. 芳香化酶抑制剂相关骨关节痛治疗研究进展[J]. 医学综述，2020，26(5)：909-914.
|
| [44] |
Hershman DL, Unger JM, Greenlee H, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial[J]. JAMA，2018，320(2)：167-176.
|
| [45] |
Genovese TJ, Mao JJ. Genetic predictors of response to acupuncture for aromatase inhibitor-associated arthralgia among breast cancer survivors[J]. Pain Med，2019，20(1)：191-194.
|
| [46] |
Goldvaser H, Barnes TA, Eruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst，2018，110(1)：31－39.
|
| [47] |
Schmidt N, Jacob L, Coleman R, et al. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom[J]. Breast Cancer Res Treat，2016，155(1)：151-157.
|
| [48] |
孙婧，王琴，汪麟，等. 绝经后早期乳腺癌接受芳香化酶抑制剂治疗后骨丢失的前瞻性研究[J]. 中华肿瘤杂志，2020，42(5)：403-407.
|
| [49] |
Baatjes KJ, Kotze MJ, Mccaul M, et al. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at in itiation of aromatase inhibitor therapy: a descriptive study[J]. PLoS One，2019，14(4)：e214153.
|
| [50] |
Trémollieres FA, Ceausu I, Depypere H, et al. Osteoporosis management in patients with breast cancer: EMAS position statement[J]. Maturitas，2017，95：65-71.
|
| [51] |
Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of clinical oncology breast cancer survivorship care guideline[J]. CA Cancer J Clin，2016，66(1)：43-73.
|
| [52] |
Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care[J]. J Natl Compr Canc Netw，2013，11 Suppl 3：S1-S50, S51.
|
| [53] |
Ligibel JA, O’Malley AJ, Fisher M, et al. Patterns of bone density evaluation in a community population treated with aromatase inhibitors[J]. Breast Cancer Res Treat，2012，134(3)：1305-1313.
|
| [54] |
Henault D, Westley T, Dumitra S, et al. Divergence from osteoporosis screening guidelines in older breast cancer patients treated with anti-estrogen therapy: a population-based cohort study[J]. Bone，2018，116：94-102.
|
| [55] |
Dalla VA, Mazziotti G, Maffezzoni F, et al. Bone mineral density and FRAX score may not predict fracture risk in patients with cancer undergoing hormone deprivation therapies[J]. J Clin Oncol，2020，38(29)：3363-3366.
|
| [56] |
Hong AR, Kim JH, Lee KH, et al. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer[J]. Osteoporos Int，2017，28(4)：1413-1422.
|
| [57] |
Lee SJ, Kim KM, Brown JK, et al. Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer[J]. Calcif Tissue Int，2015，97(6)：551-559.
|
| [58] |
Liu J, Curtis EM, Cooper C, et al. State of the art in osteoporosis risk assessment and treatment[J]. J Endocrinol Invest，2019，42(10)：1149-1164.
|
| [59] |
Leslie WD, Morin SN, Lix LM, et al. Performance of FRAX in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study[J]. J Bone Miner Res，2019，34(8)：1428-1435.
|
| [60] |
Pedersini R, Amoroso V, Maffezzoni F, et al. Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy[J]. JAMA Netw Open，2019，2(9)：e1911080.
|
| [61] |
Monteverdi S, Pedersini R, Gallo F, et al. The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy[J]. JBMR Plus，2021，5(2)：e10440.
|
| [62] |
Hans D, Teňová E, Lamy O. The trabecular bone score (TBS) complements DXA and the FRAX as a fracture risk assessment tool in routine clinical practice[J]. Curr Osteoporos Rep，2017，15(6)：521-531.
|
| [63] |
Anderson KB, Holloway-Kew KL, Mohebbi M, et al. Is trabecular bone score less affected by degenerative-changes at the spine than lumbar spine BMD？[J]. Arch Osteoporos，2018，13(1)：127.
|
| [64] |
Mariotti V, Page DB, Davydov O, et al. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: a enhanced screening approach incorporating trabecular bone score[J]. J Bone Oncol，2017，7：32-37.
|
| [65] |
Catalano A, Morabito N, Agostino RM, et al. Bone health assessment by quantitative ultrasound and dual-energy X-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors[J]. Menopause，2017，24(1)：85-91.
|
| [66] |
Catalano A, Gaudio A, Agostino RM, et al. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors[J]. J Endocrinol Invest，2019，42(11)：1337-1343.
|
| [67] |
Catalano A, Gaudio A, Morabito N, et al. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab[J]. J Endocrinol Invest，2017，40(8)：851-857.
|
| [68] |
Yao S, Laurent CA, Roh JM, et al. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study[J]. Breast Cancer Res Treat，2020，180(1)：187-195.
|
| [69] |
Fukumoto S, Soen S, Taguchi T, et al. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR[J]. J Bone Miner Metab，2020，38(2)：141-144.
|
| [70] |
Leslie WD, Morin SN, Lix LM, et al. Fracture risk in women with breast cancer initiating aromatase inhibitor therapy: a registry-based cohort study[J]. Oncologist，2019，24(11)：1432-1438.
|
| [71] |
Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss[J]. Ann Oncol，2008，19(8)：1407-1416.
|
| [72] |
Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment[J]. Ann Oncol，2011，22(12)：2546-2555.
|
| [73] |
Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG[J]. J Bone Oncol，2017，7：1-12.
|
| [74] |
Grossmann M, Ramchand SK, Milat F, et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary[J]. Med J Aust，2019，211(5)：224-229.
|
| [75] |
Coleman R, de Boer R, Eidtmann H, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant le trozole (ZO-FAST study): final 60-month results[J]. Ann Oncol，2013，24(2)：398-405.
|
| [76] |
Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a cancer care ontario and American Society of clinical oncology clinical practice guideline[J]. J Clin Oncol，2017，35(18)：2062-2081.
|
| [77] |
Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial[J]. JAMA，2017，317(1)：48-58.
|
| [78] |
Ouchi Y, Nakatsukasa K, Sakaguchi K, et al. The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results[J]. J Bone Miner Metab，2021，39(2)：224-229.
|
| [79] |
Suarez-Almazor ME, Herrera R, Lei X, et al. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab[J]. Cancer，2020，126(17)：3929-3938.
|
| [80] |
Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol，2019，20(3)：339-351.
|
| [81] |
Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and Its extension[J]. J Bone Miner Res，2018，33(2)：190-198.
|
| [82] |
Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, et al. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors[J]. Breast Cancer Res Treat，2020，179(1)：153-159.
|
| [83] |
Tremblay D, Patel V, Fifer KM, et al. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience[J]. Support Care Cancer，2018，26(1)：197-202.
|
| [84] |
Yoon S, Bae KS, Cho YS, et al. Disease progression modeling analysis of the change of bone mineral density by postoperative hormone therapies in postmenopausal patients with early breast cancer[J]. J Clin Pharmacol，2019，59(11)：1543-1550.
|